Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 10, 2016, Pages 901-915

  Wasserman, Sean ^a   Meintjes, Graeme ^a,b   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Drug resistant tuberculosis; linezolid; mitochondrial toxicity; oxazolidinones; pharmacogenomics; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

CLARITHROMYCIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SUTEZOLID; PROTEIN BINDING; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG USE; GENOMICS; HUMAN; MITOCHONDRIAL TOXICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; REVIEW; URINARY EXCRETION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG INTERACTION; ISOLATION AND PURIFICATION; METABOLISM; MITOCHONDRION; PRACTICE GUIDELINE; TOXICOGENETICS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; LINEZOLID; MITOCHONDRIA; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; PROTEIN BINDING; TOXICOGENETICS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84987720213     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1225498     Document Type: Review

References (144)

1. World Health Organization. Global Tuberculosis Report 2015. Geneva:WHO; 2015.
2. E.Pietersen, E.Ignatius, E.M.Streicher, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa:a cohort study. Lancet. 2014;383:1230–1239.
3. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. Geneva:WHO; 2016.
4. E.Nathanson, R.Gupta, P.Huamani, et al. Adverse events in the treatment of multidrug-resistant tuberculosis:results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382–1384.
5. G.B.Migliori, B.Eker, M.D.Richardson, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387–393.
6. C.Fitzpatrick, K.Floyd A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30:63–80.
7. M.Mphahlele, R.M.Warren, E.Streicher, et al. Emergence of additional resistance during standardized MDR-TB treatment. In 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease; 2015 Dec 2–6; Cape Town.
8. B.Muller, V.N.Chihota, M.Pillay, et al. Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8:e70919.
9. X.Zhang, M.E.Falagas, K.Z.Vardakas, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7:603–615.•• The most recent systematic review of the use of linezolid in drug-resistant tuberculosis treatment.
10. C.C.Zhou, S.M.Swaney, D.L.Shinabarger, et al. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother. 2002;46:625–629.
11. K.L.Leach, S.M.Swaney, J.R.Colca, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007;26:393–402.
12. S.M.Swaney, H.Aoki, M.C.Ganoza, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42:3251–3255.
13. D.M.Livermore Linezolid in vitro:mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;51(Suppl 2):ii9–16.
14. A.H.Lin, R.W.Murray, T.J.Vidmar, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41:2127–2131.
15. M.Fines, R.Leclercq. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother. 2000;45:797–802.
16. M.S.Dryden. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Suppl 4):iv7–iv15.
17. A.Di Paolo, P.Malacarne, E.Guidotti, et al. Pharmacological issues of linezolid:an updated critical review. Clin Pharmacokinet. 2010;49:439–447.
18. T.Q.Tan, R.Yogev. Clinical pharmacology of linezolid:an oxazolidinone antimicrobial agent. Expert Rev Clin Pharmacol. 2008;1:479–489.
19. T.Gee, R.Ellis, G.Marshall, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45:1843–1846.
20. P.Dehghanyar, C.Burger, M.Zeitlinger, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49:2367–2371.
21. A.Tsona, S.Metallidis, N.Foroglou, et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother. 2010;22:17–19.
22. O.W.Akkerman, R.van Altena, T.Klinkenberg, et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J. 2013;42:1750–1752.
23. J.E.Conte, J.A.Golden, J.Kipps, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475–1480.
24. D.Honeybourne, C.Tobin, G.Jevons, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51:1431–1434.
25. K.C.Chang, W.W.Yew, S.W.Cheung, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother. 2013;57:3445–3449.
26. D.L.Stevens, B.Dotter, K.Madaras-Kelly. A review of linezolid:the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004;2:51–59.
27. F.Pea, M.Furlanut, P.Cojutti, et al. Therapeutic drug monitoring of linezolid:a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605–4610.
28. J.G.Slatter, D.J.Stalker, K.L.Feenstra, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136–1145.
29. Y.Nukui, S.Hatakeyama, K.Okamoto, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128–2133.
30. K.Matsumoto, A.Takeshita, K.Ikawa, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179–181.
31. J.Mateu de Antonio, S.Grau, J.A.Morales-Molina, et al. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis. 2006;42:1500. author reply 1501
32. Y.H.Lin, V.C.Wu, I.J.Tsai, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345–351.
33. T.Han, S.Naicker, P.Ramdial, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney International. 2006;69:2243–2250.
34. K.Gandelman, T.Zhu, O.A.Fahmi, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid:in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–236.
35. M.S.Bolhuis, R.van Altena, D.van Soolingen, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013;42:1614–1621.
36. B.C.Gebhart, B.C.Barker, B.A.Markewitz. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476–479.
37. M.S.Bolhuis, R.van Altena, D.R.Uges, et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother. 2010;54:5418–5419.
38. C.Gervasoni, F.R.Simonetti, C.Resnati, et al. Prolonged inductive effect of rifampicin on linezolid exposure. Eur J Clin Pharmacol. 2015;71:643–644.
39. K.R.Lawrence, M.Adra, P.K.Gillman. Serotonin toxicity associated with the use of linezolid:a review of postmarketing data. Clin Infect Dis. 2006;42:1578–1583.
40. S.E.Beekmann, D.N.Gilbert, P.M.Polgreen, et al. Toxicity of extended courses of linezolid:results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis. 2008;62:407–410.
41. S.Packer, S.A.Berman. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry. 2007;164:346–347.
42. A.C.Go, L.K.Golightly, G.R.Barber, et al. Linezolid interaction with serotonin reuptake inhibitors:report of two cases and incidence assessment. Drug Metabol Drug Interact 2010, 2541–47.
43. J.J.Taylor, J.W.Wilson, L.L.Estes. Linezolid and serotonergic drug interactions:a retrospective survey. Clin Infect Dis. 2006;43:180–187.
44. Pfizer laboratories. Approved package insert:Zyvoxid [Internet]. 22 May 2015. [cited 2016 Aug 22]. Available from:http://labeling.pfizer.com/ShowLabeling.aspx?id=1045.
45. E.Rey-Jurado, G.Tudo, D.Soy, et al. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model. Int J Antimicrob Agents. 2013;42:524–530.
46. E.Rey-Jurado, G.Tudo, J.P.de la Bellacasa, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2013;41:278–280.
47. B.Bozdogan, P.C.Appelbaum. Oxazolidinones:activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113–119.
48. D.J.Diekema, R.N.Jones. Oxazolidinone antibiotics. The Lancet. 2001;358:1975–1982.
49. L.Alcala, M.J.Ruiz-Serrano, C.Perez-Fernandez Turegano, et al. in vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003;47:416–417.
50. P.C.Yip, K.M.Kam, E.T.Lam, et al. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2013;42:96–97.
51. T.Weiss, N.Schonfeld, R.Otto-Knapp, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J. 2015;45:285–287.
52. T.Schon, P.Jureen, E.Chryssanthou, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2011;15:502–509.
53. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). European society of clinical microbiology and infectious diseases [Internet]. Linezolid/Mycobacterium tuberculosis interbational MIC distribution – reference database 2016-08-22. [cited 2016 Aug 22]. Available from:http://mic.eucast.org/Eucast2/regShow.jsp?Id=37679.
54. M.H.Cynamon, S.P.Klemens, C.A.Sharpe, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1999;43:1189–1191.
55. K.N.Williams, C.K.Stover, T.Zhu, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2009;53:1314–1319.
56. R.Cremades, J.C.Rodriguez, E.Garcia-Pachon, et al. Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model. Apmis. 2011;119:304–308.
57. R.Dietze, D.J.Hadad, B.McGee, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178:1180–1185.
58. N.Ndjeka, F.Conradie, K.Schnippel, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting:an interim cohort analysis. Int J Tuberc Lung Dis. 2015;19:979–985.
59. M.Zhang, C.Sala, N.Dhar, et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58:3217–3223.
60. W.Zhao, Z.Guo, M.Zheng, et al. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice. Int J Antimicrob Agents. 2014;43:148–153.
61. R.Tasneen, F.Betoudji, S.Tyagi, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2016;60:270–277.
62. M.Lee, J.Lee, M.W.Carroll, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–1518.•• The first clinical trial of linezolid in XDR tuberculosis treatment.
63. M.Lee, S.N.Cho, C.E.Barry3rd, et al. Linezolid for XDR-TB – final study outcomes. N Engl J Med. 2015;373:290–291.
64. S.Tang, L.Yao, X.Hao, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB:a study in China. Eur Respir J. 2015;45:161–170.
65. J.Hughes, P.Isaakidis, A.Andries, et al. Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. Eur Respir J. 2015;46:271–274.
66. E.Mohr, H.Cox, L.Wilkinson, et al. Encouraging early outcomes for individualized treatment of multidrug-resistant tuberculosis using bedaquiline and linezolid in Khayelitsha. In 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease; 2015 Dec 2–6; Cape Town
67. S.Abe, K.Chiba, B.Cirincione, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease:application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–1078.
68. Y.Tsuji, E.Yukawa, Y.Hiraki, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013;53:967–973.
69. H.McIlleron, P.Wash, A.Burger, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50:1170–1177.
70. D.Pacheu-Grau, A.Gomez-Duran, M.J.Lopez-Perez, et al. Mitochondrial pharmacogenomics:barcode for antibiotic therapy. Drug Discov Today. 2010;15:33–39.• Excellent review of mitochondrial pharmacogenomics in antibiotic therapy.
71. M.W.Gray, G.Burger, B.F.Lang. The origin and early evolution of mitochondria. Genome Biol. 2001;2:reviews 1018.1–reviews 1018.5.
72. R.Rossignol, B.Faustin, C.Rocher, et al. Mitochondrial threshold effects. Biochem J. 2003;370:751–762.
73. L.Xiong, P.Kloss, S.Douthwaite, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol. 2000;182:5325–5331.
74. M.Saraste. Oxidative phosphorylation at the fin de siecle. Science. 1999;283:1488–1493.
75. A.Soriano, O.Miro, J.Mensa. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353:2305–2306.
76. G.Garrabou, A.Soriano, S.Lopez, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2007;51:962–967.
77. A.S.De Vriese, R.V.Coster, J.Smet, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42:1111–1117.• Key study demonstrating the link between linezolid-induced adverse events and mitochondrial toxicity.
78. E.E.McKee, M.Ferguson, A.T.Bentley, et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 2006;50:2042–2049.
79. E.E.Nagiec, L.Wu, S.M.Swaney, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005;49:3896–3902.
80. M.R.Sharma, E.C.Koc, P.P.Datta, et al. Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. Cell. 2003;115:97–108.
81. A.N.Brown, G.L.Drusano, J.R.Adams, et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio. 2015;6:e01741–01715.
82. A.E.Barnhill, M.T.Brewer, S.A.Carlson. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob Agents Chemother. 2012;56:4046–4051.
83. L.Palenzuela, N.M.Hahn, R.P.NelsonJr., et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005;40:e113–116.
84. J.L.Del Pozo, N.Fernandez-Ros, E.Saez, et al. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother. 2014;58:4227–4229.
85. A.B.Mehta, T.Vulliamy, E.C.Gordon-Smith, et al. A new genetic polymorphism in the 16S ribosomal RNA gene of human mitochondrial DNA. Ann Hum Genet. 1989;53:303–310.
86. T.Song, M.Lee, H.-S.Jeon, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015;2:1627–1633.•• Defines the relationship between linezolid exposure and mitochondrial toxicity in a clinical cohort.
87. D.Boutoille, O.Grossi, A.Depatureaux, et al. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis. Eur J Intern Med. 2009;20:e134–135.
88. A.M.Bressler, S.M.Zimmer, J.L.Gilmore, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4:528–531.
89. M.Narita, B.T.Tsuji, V.L.Yu. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189–1197.
90. M.S.Bolhuis, S.Tiberi, G.Sotgiu, et al. Linezolid tolerability in multidrug-resistant tuberculosis:a retrospective study. Eur Respir J. 2015;46:1205–1207.
91. K.Brinkman, H.J.ter Hofstede, D.M.Burger, et al. Adverse effects of reverse transcriptase inhibitors:mitochondrial toxicity as common pathway. Aids. 1998;12:1735–1744.
92. E.Jacotot, L.Ravagnan, M.Loeffler, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med. 2000;191:33–46.
93. G.Sotgiu, R.Centis, L.D’Ambrosio, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB:systematic review and meta-analysis. Eur Respir J. 2012;40:1430–1442.
94. R.K.Flamm, R.E.Mendes, P.A.Hogan, et al. Linezolid surveillance results for the United States (LEADER Surveillance Program 2014). Antimicrob Agents Chemother. 2016;60:2273–2280.
95. V.G.Meka, H.S.Gold. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39:1010–1015.
96. D.Hillemann, S.Rusch-Gerdes, E.Richter. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother. 2008;52:800–801.
97. E.Richter, S.Rusch-Gerdes, D.Hillemann. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51:1534–1536.
98. K.S.Long, B.Vester. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother. 2012;56:603–612.
99. P.Beckert, D.Hillemann, T.A.Kohl, et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 2012;56:2743–2745.• First description of association of rplC mutation with linezolid resistance in M. tuberculosis and also provides good discussion.
100. G.G.Makafe, Y.Cao, Y.Tan, et al. Role of the Cys154Arg substitution in ribosomal protein L3 in oxazolidinone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60:3202–3206.
101. Z.Zhang, Y.Pang, Y.Wang, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents. 2014;43:231–235.
102. P.Sander, L.Belova, Y.G.Kidan, et al. Ribosomal and non-ribosomal resistance to oxazolidinones:species-specific idiosyncrasy of ribosomal alterations. Mol Microbiol. 2002;46:1295–1304.
103. I.Escribano, J.C.Rodriguez, B.Llorca, et al. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy. 2007;53:397–401.
104. A.A.Velayati, P.Farnia, T.A.Ibrahim, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis:using transmission electron microscopy. Chemotherapy. 2009;55:303–307.
105. I.Parwati, R.van Crevel, D.van Soolingen. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis. 2010;10:103–111.
106. T.S.Huang, Y.C.Liu, C.L.Sy, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother. 2008;52:2226–2227.
107. A.Louie, H.S.Heine, K.Kim, et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother. 2008;52:2486–2496.
108. J.C.Rodriguez, L.Cebrian, M.Lopez, et al. Mutant prevention concentration:comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother. 2004;53:441–444.
109. S.Srivastava, J.G.Pasipanodya, C.Meek, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204:1951–1959.
110. J.G.Pasipanodya, S.Srivastava, T.Gumbo. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55:169–177.
111. C.R.Rayner, L.M.Baddour, M.C.Birmingham, et al. Linezolid in the treatment of osteomyelitis:results of compassionate use experience. Infection. 2004;32:8–14.
112. A.K.Meagher, A.Forrest, C.R.Rayner, et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47:548–553.
113. D.Andes, M.L.van Ogtrop, J.Peng, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46:3484–3489.
114. L.M.Boak, J.Li, C.R.Rayner, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51:1287–1292.
115. J.W.Alffenaar, R.van Altena, I.M.Harmelink, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet. 2010;49:559–565.
116. R.S.Wallis, W.M.Jakubiec, V.Kumar, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis. 2010;202:745–751.
117. P.Barry, D.Deck, A.Farkas. Pharmacokinetic modeling of linezolid dosing regimens for multidrug resistant tuberculosis. Abstract 406, ID Week; 2014 Oct 8–12; Philadelphia (PA).
118. L.Zhang, Y.Pang, X.Yu, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection. 2014;42:705–711.
119. Y.Liu, P.Bao, D.Wang, et al. Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China:a hospital-based retrospective study. Jpn J Infect Dis. 2015;68:244–247.
120. W.J.Koh, Y.R.Kang, K.Jeon, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis:updated analysis of 51 patients. J Antimicrob Chemother. 2012;67:1503–1507.• The only study to evaluate a 300-mg daily dose of linezolid from the beginning of therapy.
121. H.Liu, Y.Wang, N.Liu, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China. Indian J Med Microbiol. 2015;33(Suppl):164–165.
122. R.S.Wallis, C.Wang, T.M.Doherty, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2010;10:68–69.
123. R.S.Wallis, S.A.Vinhas, J.L.Johnson, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis. 2003;187:270–278.
124. A.Alsultan, C.A.Peloquin. Therapeutic drug monitoring in the treatment of tuberculosis:an update. Drugs. 2014;74:839–854.
125. J.W.Alffenaar, J.G.Kosterink, R.van Altena, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010;32:97–101.
126. H.Y.Dong, J.Xie, L.H.Chen, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33:1029–1035.
127. K.Matsumoto, A.Shigemi, A.Takeshita, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid:a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242–247.
128. F.Pea, P.Viale, P.Cojutti, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034–2042.
129. M.S.Bolhuis, R.van Altena, K.van Hateren, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57:3676–3680.
130. D.H.Vu, J.W.Alffenaar, P.M.Edelbroek, et al. Dried blood spots:a new tool for tuberculosis treatment optimization. Curr Pharm Des. 2011;17:2931–2939.
131. D.H.Vu, M.S.Bolhuis, R.A.Koster, et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012;56:5758–5763.
132. D.Cattaneo, J.W.Alffenaar, M.Neely. Drug monitoring and individual dose optimization of antimicrobial drugs:oxazolidinones. Expert Opin Drug Metab Toxicol. 2016;12:533–544.
133. V.Balasubramanian, S.Solapure, H.Iyer, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58:495–502.
134. J.J.Furin, J.Du Bois, E.van Brakel, et al. Early bactericidal activity of AZD5847 in pulmonary tuberculosis. In 46th Union World Conference on Lung Health; 2015 Dec 2–6; Cape Town.
135. R.S.Wallis, M.Maeurer, P.Mwaba, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016;16:e34–46.
136. J.W.Alffenaar, T.van der Laan, S.Simons, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother. 2011;55:1287–1289.
137. K.N.Williams, S.J.Brickner, C.K.Stover, et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med. 2009;180:371–376.
138. R.S.Wallis, R.Dawson, S.O.Friedrich, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014;9:e94462.
139. R.S.Wallis, W.Jakubiec, V.Kumar, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother. 2011;55:567–574.
140. B.McGee, R.Dietze, D.J.Hadad, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009;53:3981–3984.
141. W.J.Koh, O.J.Kwon, H.Gwak, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009;64:388–391.
142. J.W.Mouton, P.G.Ambrose, R.Canton, et al. Conserving antibiotics for the future:new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat. 2011;14:107–117.
143. J.Pasipanodya, T.Gumbo. An oracle:antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother. 2011;55:24–34.
144. E.Lessem, H.Cox, C.Daniels, et al. Access to new medications for the treatment of drug-resistant tuberculosis:patient, provider and community perspectives. Int J Infect Dis. 2015;32:56–60.